VanEck Biotech ETF

BBH

Market cap $399M

Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to the 25 positions in VanEck Biotech ETF VanEck Biotech ETF has a slightly lower expense ratio of 0.35% while Invesco S&P 500 Equal Weight Health Care ETF charges 0.40% Invesco S&P 500 Equal Weight Health Care ETF has experienced a significantly lower five-year maximum drawdown than the biotech fund

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.

iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries significantly greater historical price volatility iShares U.S. Healthcare ETF offers a higher dividend yield and lower five-year maximum drawdown for income-focused investors

State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40% over the last five years.

Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.

Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Check out our daily newsletter!

The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.

U.S. biotechnology industry trade group BIO worked with the Food and Drug ​Administration on plans announced on Monday to speed ‌clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley ​said on Tuesday.

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.